NDAQ:SRRK) Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular ...

马萨诸塞州剑桥 - 生物制药公司Scholar Rock（纳斯达克股票代码：SRRK）今天宣布了其针对脊髓性肌萎缩症（SMA）患者的apitegromab第三期SAPPHIRE临床试验的积极结果。该研究达到了主要终点，显示接受apitegromab治疗的患者在运动功能方面相比接受安慰剂的患者有统计学意义的显著改善。 这项包括2-12岁患者的试验显示，接受apitegromab治疗的患者在Hamme ...

The Phase III SAPPHIRE trial (NCT05156320) evaluating Scholar Rock’s lead pipeline candidate apitegromab, met its primary ...

There's plenty of smiles, fewer tattoos and a one or two questionable fashion choices on display from these Middlesbrough ...

From the famous Kubla Kahn formation at Kartchner Caverns to the deep history of Colossal Cave, here's what to know about 10 ...

It can be a controversial look, but wearing rings may just unlock your sense of self-expression—and, trust me, people notice.

The transaction was a milestone for Onyx and SWIAT, which are collaborating to develop digital asset issuance products on ...

Jamie Dimon, the anti-crypto CEO of the somehow pro-crypto JPMorgan, just basically admitted that he knows our current global ...

The 2023 Subaru Forester Wilderness is the most off-road-ready version of Subaru's popular crossover wagon. All information ...

Following the study, 98% of the SAPPHIRE study patient population (185 out of 188) joined the ongoing ONYX open-label ...

This season's high jewelry captivates, creating an elegant romance and becoming the pieces for the most sought-after holiday ...

From the red carpet to the runways, the jewellery brooch is making a comeback in a big way. Here's what you need to know.